A 71-year-old woman presented with a high-grade fever, neck pain, anemia and thrombocytopenia. After performing further examinations, we concluded that she had simultaneously developed large vessel vasculitis and myelodysplastic syndrome (MDS). Although glucocorticoid administration improved her clinical symptoms, the MDS transformed into acute myeloid leukemia and she died one year after receiving the diagnosis. The occurrence of immune-mediated disorders in patients with MDS is a well-known phenomenon; however, large vessel vasculitis is a rare complication of MDS. Our case suggests that the association between systemic vasculitis and MDS may result in poor outcomes.
Introduction
Myelodysplastic syndrome (MDS) is a clonal stem cell disorder characterized by ineffective hematopoiesis and the potential to progress to acute leukemia. The etiology of MDS is unclear; however, there is some evidence that the cytopenia observed in several forms of MDS is caused by immune-mediated myelosuppression (1) . In addition, previous reports have shown that various types of immunemediated disorders, including vasculitis, occur in some patients with MDS; however, leukocytoclastic vasculitis and small vessel vasculitis are more common than vasculitis developing in large vessels (2) (3) (4) . The conventional therapy for large vessel vasculitis involves the administration of glucocorticoids, in some cases coadministered with other immunosuppressive drugs, although the cause of the disease remains unknown. This report describes a rare case of an elderly woman who simultaneously developed large vessel vasculitis and MDS.
Case Report
A 71-year-old woman with a high-grade fever and neck pain was admitted to our hospital. She had been diagnosed with breast cancer three years earlier and had undergone mastectomy and chemotherapy with 5-fuluorouracil, farmorubicin and cyclophosphamide. The chemotherapy was completed six months after the operation. She visited another hospital due to a fever and low back pain that had occurred one week before admission to our institution. Laboratory tests revealed a high serum level of C-reactive protein (CRP, 20.6 mg/dL) with anemia (hemoglobin, 9.9 g/dL) and thrombocytopenia (platelet count, 3.3×10 3 /μL), although the whole blood cell count obtained at another hospital one month before the current admission was normal. Treatment with antibiotics for one week failed to improve the patient's symptoms; therefore, she was transferred to our hospital. She had no habit of either smoking or consuming alcohol. She had a medical history of diabetes mellitus; however, her treatment (glimepiride) had not been changed for several years.
She presented with weight loss (2 kg over three weeks) and a high fever (>38 ). She had noticed that the pain spread from her low back to her neck, although she had no manifestations such as myalgia or arthralgia indicating the presence of polymyalgia rheumatica. A physical examination revealed no rashes, laterality of blood pressure or bruits in the carotid or funicular temporal arteries. The laboratory data showed a high serum level of CRP with anemia, thrombocytopenia and liver dysfunction (Table 1) . Although a red blood cell transfusion had been administered once before admission, it was likely that the high serum level of ferritin was primarily caused by the persistent inflammation. Ultrasound, contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) showed marked thickening of the arterial walls. An 18 F-fluorodeoxyglucose positron emission tomography/CT (PET-CT) scan detected abnormal uptake in the aorta and carotid artery ( Figure) . A temporal artery biopsy showed no evidence of giant cell arteritis (GCA). A bone marrow aspiration analysis demonstrated normal cellular marrow with dysplastic changes in two hematopoietic lineages and <2% blasts. A cytogenetic study revealed t(6:11)(q27:q23), 46, XY, and the patient was diagnosed with MDS, refractory cytopenia with multilineage dysplasia (RCMD, 2008 WHO classification) and an inter- national prognostic scoring system (IPSS) score of 1.0. Therefore, we concluded that she had large vessel vasculitis and MDS simultaneously. For treatment, glucocorticoids (1.0 mg/kg/day) were administered orally. The patient's clinical symptoms, marked thickening of the arterial wall on CT, high serum level of CRP and liver dysfunction improved soon after the initiation of treatment, although the anemia and thrombocytopenia remained unchanged, and red blood cell and platelet transfusions were needed approximately once a week. Unfortunately, the MDS transformed into acute myeloid leukemia (AML) four months later, and she died one year after receiving the diagnosis.
Discussion
The occurrence of immune-mediated disorders in patients with MDS is well known. Previous reports have shown that the incidence of autoimmune phenomena is between 10% and 18.5% (2, 3, 5) . Vasculitis associated with MDS has been reported, although leukocytoclastic vasculitis and small vessel vasculitis are more common than vasculitis developing in larger vessels. Behcet's disease, which is considered to be a type of vasculitis, has also been reported to be complicated by MDS with trisomy 8 in Asian populations.
The pathogenesis of immune-mediated disorders in patients with MDS is unclear. Barrett et al. proposed that MDS clones express neoantigens or overexpress antigens, triggering the expansion and activation of cytotoxic Tcells (6). These T-cells secrete cytokines, such as TNF-α and IFN-γ, that promote the apoptosis of normal progenitor cells. The serum TNF-α levels in patients with systemic vasculitis are significantly higher than those observed in healthy controls (7), and anti-TNF agents represent an efficient therapy for refractory large vessel vasculitis (8) , suggesting that these cytokines play an important role in the development of immune disorders in patients with MDS, although there is no clear evidence yet to support this hypothesis.
Large vessel vasculitis includes Takayasu arteritis (TA) and GCA, although it remains difficult to classify these two diseases in some cases. The age of onset in cases of large vessel vasculitis has frequently been discussed with respect to the diagnosis (9) . However, a recent report demonstrated that the clinical features of TA do not vary between patients with an age of onset over 40 years and those who are younger, suggesting that it is inappropriate to distinguish these diseases based only on the age of onset (10) . In our case, a PET-CT scan detected abnormal uptake primarily in the aorta, and a temporal artery biopsy revealed normal findings without evidence of giant cells. Therefore, we are unable to deny the possibility of TA or diagnose GCA, although the age of onset implies that the patient developed GCA. Large future clinical trials are needed to assess the precise diagnosis in such cases.
Hollanda et al. reported no differences in the prognosis between MDS patients with and without immune-mediated disorders (4). The authors added that the presence of systemic vasculitis is related to a poor prognosis and rapid clinical deterioration, although their study did not include patients with large vessel vasculitis. A four-year prospective study of 70 patients showed that the presence of immunemediated disorders does not influence the prognosis or mortality, although that study included only two patients with systemic vasculitis (not including leukocytoclastic vasculitis as systemic vasculitis) (3). Moreover, these two studies excluded MDS patients complicated with immune-mediated disorders following chemotherapy, although most patients with therapy-related MDS are known to have a poor prognosis and abnormal karyotypes.
The influence of large vessel vasculitis on the prognosis of patients with MDS is unclear. In most cases of MDS complicated by rheumatic disease, the hematological disorder is not ameliorated by immunosuppressive therapy, including glucocorticoids, although the immune-mediated phenomena improve. In this case, although treatment with glu-cocorticoids improved the vasculitis, the MDS progressed to AML and the patient died only one year after receiving the diagnosis. To our knowledge, only three cases of GCA and four cases of TA complicated by MDS have been previously reported (we excluded a report in French) (11) (12) (13) (14) (15) (16) (Table 2) . Four of the patients, including the present patient, were diagnosed with MDS and large vessel vasculitis simultaneously. Although we were unable to exclude the possibility that MDS had occurred silently before the vasculitis developed in the three previous cases, the laboratory data obtained just before the vasculitis occurred in the current patient revealed that the MDS and vasculitis had developed simultaneously in the present case.
In all cases of MDS and large vessel vasculitis, including the present case, treatment with glucocorticoids rapidly improved the symptoms of vasculitis; however, these drugs failed to ameliorate the MDS. Of note, one patient with MDS of RARS with an IPSS of 0.5 who was considered to have a relatively good prognosis among MDS patients surprisingly progressed to AML only four months after vasculitis developed, the same duration as that observed in our case. Except for two cases, most of the MDS patients with superimposed large vessel vasculitis died or progressed to AML within a short period of time. These observations suggest that a poor prognosis results from the association between systemic vasculitis and MDS, although there is insufficient evidence to conclude that complications with large vessel vasculitis may influence the prognosis of MDS. The accumulation of more clinical cases is required to determine the prognostic value of the complication of large vessel vasculitis with respect to the poor prognosis of MDS patients.
MDS occurring after treatment for tumors is considered to be therapy-related. Therapy-related MDS is commonly associated with the use of chemotherapeutic drugs and/or radiotherapy. The current patient had received chemotherapy with cyclophosphamide and 5-fulorouracil for breast cancer three years prior to admission to our hospital. The development of MDS after treatment for breast cancer with cyclophosphamide and 5-fulorouracil is rare (17, 18) ; however, it is hard to deny the possibility that the present patient's MDS was associated with chemotherapy. As a result, the possibility of MDS complicated by systemic vasculitis should therefore be considered in the differential diagnosis of patients treated with chemotherapy, although there are no previous reports of therapy-related MDS patients complicated with large vessel vasculitis.
We herein presented a rare case of large vessel vasculitis associated with MDS. Aggressive therapy for MDS is required in patients with systemic vasculitis and MDS under special attention for the possibility of infection during immunosuppressive therapy.
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